Amneal Pharmaceuticals (AMRX) Debt to Equity (2017 - 2025)
Historic Debt to Equity for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$23.41.
- Amneal Pharmaceuticals' Debt to Equity rose 852.81% to -$23.41 in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.41, marking a year-over-year increase of 852.81%. This contributed to the annual value of -$21.79 for FY2024, which is 11699.77% down from last year.
- Per Amneal Pharmaceuticals' latest filing, its Debt to Equity stood at -$23.41 for Q3 2025, which was up 852.81% from -$21.65 recorded in Q2 2025.
- In the past 5 years, Amneal Pharmaceuticals' Debt to Equity ranged from a high of $128.18 in Q4 2023 and a low of -$41.79 during Q2 2024
- For the 5-year period, Amneal Pharmaceuticals' Debt to Equity averaged around $3.64, with its median value being $7.1 (2021).
- In the last 5 years, Amneal Pharmaceuticals' Debt to Equity soared by 78923.61% in 2023 and then plummeted by 33607.65% in 2024.
- Amneal Pharmaceuticals' Debt to Equity (Quarter) stood at $7.43 in 2021, then skyrocketed by 93.91% to $14.41 in 2022, then surged by 789.24% to $128.18 in 2023, then plummeted by 117.0% to -$21.79 in 2024, then fell by 7.43% to -$23.41 in 2025.
- Its last three reported values are -$23.41 in Q3 2025, -$21.65 for Q2 2025, and -$18.51 during Q1 2025.